Mirum Pharmaceuticals (NASDAQ:MIRM) Earns Buy Rating from HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $66.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 96.08% from the company’s current price.

A number of other equities research analysts have also recently weighed in on MIRM. JMP Securities upped their price target on Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 18th. JPMorgan Chase & Co. raised their target price on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, June 18th. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th. Finally, Stifel Nicolaus restated a “buy” rating and set a $48.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 17th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $53.64.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM traded up $0.55 on Friday, hitting $33.66. 232,092 shares of the company’s stock were exchanged, compared to its average volume of 607,827. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.68 and a quick ratio of 3.47. The firm’s 50-day moving average price is $26.23 and its two-hundred day moving average price is $27.26. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -9.04 and a beta of 1.10. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The business had revenue of $69.22 million during the quarter, compared to analysts’ expectations of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. On average, research analysts expect that Mirum Pharmaceuticals will post -1.66 EPS for the current year.

Insider Activity

In other news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Pamela Vig sold 30,559 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $34.00, for a total value of $1,039,006.00. Following the transaction, the insider now directly owns 27,406 shares of the company’s stock, valued at approximately $931,804. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The disclosure for this sale can be found here. Company insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. AJOVista LLC purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth about $40,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $41,000. StepStone Group LP purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $135,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 447.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock worth $159,000 after acquiring an additional 4,408 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $194,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.